Reaction: Citalopram to 1 product
- Reaction
- Reaction type
- oxidation
- Direction
- Major circulating metabolite?
- No
- Spontaneous?
- No
- Activity
- unknown
- References
- Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M: The KEGG resource for deciphering the genome. Nucleic Acids Res. 2004 Jan 1;32(Database issue):D277-80. [Article]
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [Article]
- Bezchlibnyk-Butler K, Aleksic I, Kennedy SH: Citalopram--a review of pharmacological and clinical effects. J Psychiatry Neurosci. 2000 May;25(3):241-54. [Article]
- Sangkuhl K, Klein TE, Altman RB: PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72. doi: 10.1097/FPC.0b013e328346063f. [Article]
- Rochat B, Kosel M, Boss G, Testa B, Gillet M, Baumann P: Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol. 1998 Jul 1;56(1):15-23. doi: 10.1016/s0006-2952(98)00008-2. [Article]
- FDA Approved Drug Products: CELEXA (citalopram) tablets, for oral use (August 2023) [Link]
- Comments
- Not Available
- Enzymes
Enzyme Km Vmax Role Amine oxidase [flavin-containing] A Not Available Not Available implied Amine oxidase [flavin-containing] B Not Available Not Available implied
